CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (34,863)	$ (22,955)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of discount on investments	(84)	(267)
Amortization of right of use assets	392	390
Changes in fair value of the warrants	14,373
Depreciation expense	282	454
Stock-based compensation including ESPP	2,648	3,664
Changes in operating assets and liabilities:
Other assets	204	2,086
Accounts payable	325	(1,915)
Accrued liabilities	(4,800)	(937)
Operating lease liabilities	(636)	(584)
Deferred revenue from collaborations	(84)	(2,323)
Deferred revenue from customers	(503)
Net cash and cash equivalents used in operating activities	(22,746)	(22,387)
Activities in available-for-sale investments:
Maturities of short-term investments		20,000
Purchase of short-term investments	(88,573)
Purchases of property and equipment	(69)	(7)
Net cash and cash equivalents (used in) provided by investing activities	(88,642)	19,993
Cash flows from financing activities:
Payments on finance lease	(19)	(24)
Proceeds from the exercise of common stock option		23
Net cash and cash equivalents used in financing activities	(19)	(1)
Net decrease in cash, cash equivalents, and restricted cash	(111,407)	(2,395)
Cash, cash equivalents, and restricted cash, beginning of period	135,774	81,463
Cash, cash equivalents, and restricted cash, end of period	24,367	79,068
Reconciliation to amounts on the Consolidated Balance Sheet:
Cash and cash equivalents	24,151	78,671
Restricted cash	216	397
Cash, cash equivalents, and restricted cash, end of period	24,367	79,068
Supplemental disclosures of noncash financing and investing activities:
Mark to market adjustment for available-for-sale investments	$ (69)	98
Vesting of early exercised options		$ 20